William Pridgen - Mar 23, 2022 Form 4 Insider Report for Virios Therapeutics, Inc. (VIRI)

Role
Director
Signature
/s/ Greg Duncan, Attorney-in-Fact
Stock symbol
VIRI
Transactions as of
Mar 23, 2022
Transactions value $
$12,002
Form type
4
Date filed
3/24/2022, 02:52 PM
Previous filing
Jan 28, 2022
Next filing
Mar 30, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIRI Common Stock Purchase $12K +2.2K +10.86% $5.46* 22.4K Mar 23, 2022 401 (k) Account F1, F2, F3
holding VIRI Common Stock 709K Mar 23, 2022 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.37 to $5.48, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. ("Virios"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.
F2 Reflects corrected holdings, as prior reports incorrectly understated indirect holdings and overstated direct holdings, by 1,500 shares.
F3 The number of shares reported are indirectly held within the Reporting Person's 401(k) account and are invested in the Tuscaloosa Surgical Assoc PC 401k U/A Dtd Jan 1, 2001 of which the Reporting Person is trustee.